Regeneron, CytomX Ink Potentially $2B Bispecific Immunotherapy Deal

Regeneron and CytomX Therapeutics inked a deal valued at up to $2 billion to develop next-generation bispecific immunotherapies for cancer, the companies announced Thursday.

Regeneron will pair its Veloci-Bi bispecific antibody development platform with CytomX Therapeutics’ Probody therapeutic platform to develop bispecifics that are expected to become active by proteases in the tumor microenvironment.